Simvastatin, a HMG-CoA reductase inhibitor, is prescribed worldwide to patients with hypercholesterolemia. Although simvastatin is well tolerated, side effects like myotoxicity are reported. The mechanism for statin-induced myotoxicity is still poorly understood. Reports have suggested impaired mitochondrial dysfunction as a contributor to the observed myotoxicity. In this regard, we wanted to study the effects of simvastatin on glucose metabolism and the activity of legumain, a cysteine protease. Legumain, being the only known asparaginyl endopeptidase, has caspase-like properties and is described to be involved in apoptosis. Recent evidences indicate a regulatory role of both glucose and statins on cysteine proteases in monocytes. Satellite cells were isolated from the Musculus obliquus internus abdominis of healthy human donors, proliferated and differentiated into polynuclear myotubes. Simvastatin with or without mevalonolactone, farnesyl pyrophosphate or geranylgeranyl pyrophosphate were introduced on day 5 of differentiation. After 48 h, cells were either harvested for immunoblotting, ELISA, cell viability assay, confocal imaging or enzyme activity analysis, or placed in a fuel handling system with [14C]glucose or [3H]deoxyglucose for uptake and oxidation studies. A dose-dependent decrease in both glucose uptake and oxidation were observed in mature myotubes after exposure to simvastatin in concentrations not influencing cell viability. In addition, simvastatin caused a decrease in maturation and activity of legumain. Dysregulation of glucose metabolism and decreased legumain activity by simvastatin points out new knowledge about the effects of statins on skeletal muscle, and may contribute to the understanding of the myotoxicity observed by statins.
References
[1]
Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, et al. (2004) Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364: 771–777.
[2]
Pedersen TR (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383–1389.
[3]
Sinzinger H, Wolfram R, Peskar BA (2002) Muscular side effects of statins. J Cardiovasc Pharmacol 40: 163–171.
[4]
Arora R, Liebo M, Maldonado F (2006) Statin-induced myopathy: the two faces of Janus. J Cardiovasc Pharmacol Ther 11: 105–112.
[5]
Sakamoto K, Honda T, Yokoya S, Waguri S, Kimura J (2007) Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers. FASEB J 21: 4087–4094.
[6]
Sakamoto K, Wada I, Kimura J (2011) Inhibition of Rab1 GTPase and endoplasmic reticulum-to-Golgi trafficking underlies statin's toxicity in rat skeletal myofibers. J Pharmacol Exp Ther 338: 62–69.
[7]
Sirvent P, Mercier J, Vassort G, Lacampagne A (2005) Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle. Biochem Biophys Res Commun 329: 1067–1075.
[8]
Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, et al. (1993) Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 33: 226–229.
[9]
Kwak HB, Thalacker-Mercer A, Anderson EJ, Lin CT, Kane DA, et al. (2012) Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. Free Radic Biol Med 52: 198–207.
[10]
Larsen S, Stride N, Hey-Mogensen M, Hansen CN, Bang LE, et al. (2013) Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. J Am Coll Cardiol 61: 44–53.
[11]
Malenda A, Skrobanska A, Issat T, Winiarska M, Bil J, et al. (2012) Statins impair glucose uptake in tumor cells. Neoplasia 14: 311–323.
[12]
Chen JM, Dando PM, Rawlings ND, Brown MA, Young NE, et al. (1997) Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase. J Biol Chem 272: 8090–8098.
[13]
Liu C, Sun C, Huang H, Janda K, Edgington T (2003) Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res 63: 2957–2964.
[14]
Papaspyridonos M, Smith A, Burnand KG, Taylor P, Padayachee S, et al. (2006) Novel candidate genes in unstable areas of human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 26: 1837–1844.
[15]
Haugen MH, Johansen HT, Pettersen SJ, Solberg R, Brix K, et al. (2013) Nuclear legumain activity in colorectal cancer. PLoS One 8: e52980.
[16]
Wu B, Yin J, Texier C, Roussel M, Tan KS (2010) Blastocystis legumain is localized on the cell surface, and specific inhibition of its activity implicates a pro-survival role for the enzyme. J Biol Chem 285: 1790–1798.
[17]
Liu Z, Jang SW, Liu X, Cheng D, Peng J, et al. (2008) Neuroprotective actions of PIKE-L by inhibition of SET proteolytic degradation by asparagine endopeptidase. Mol Cell 29: 665–678.
[18]
Shirahama-Noda K, Yamamoto A, Sugihara K, Hashimoto N, Asano M, et al. (2003) Biosynthetic processing of cathepsins and lysosomal degradation are abolished in asparaginyl endopeptidase-deficient mice. J Biol Chem 278: 33194–33199.
[19]
Abisi S, Burnand KG, Humphries J, Waltham M, Taylor P, et al. (2008) Effect of statins on proteolytic activity in the wall of abdominal aortic aneurysms. Br J Surg 95: 333–337.
[20]
Wang ZH, Liu XL, Zhong M, Zhang LP, Shang YY, et al. (2010) Pleiotropic effects of atorvastatin on monocytes in atherosclerotic patients. J Clin Pharmacol 50: 311–319.
[21]
Halfon S, Patel S, Vega F, Zurawski S, Zurawski G (1998) Autocatalytic activation of human legumain at aspartic acid residues. FEBS Lett 438: 114–118.
[22]
Li DN, Matthews SP, Antoniou AN, Mazzeo D, Watts C (2003) Multistep autoactivation of asparaginyl endopeptidase in vitro and in vivo. J Biol Chem 278: 38980–38990.
[23]
Smith R, Johansen HT, Nilsen H, Haugen MH, Pettersen SJ, et al. (2012) Intra- and extracellular regulation of activity and processing of legumain by cystatin E/M. Biochimie 94: 2590–2599.
[24]
Moheimani F, Kim CH, Rahmanto AS, van Reyk DM, Davies MJ (2012) Inhibition of lysosomal function in macrophages incubated with elevated glucose concentrations: a potential contributory factor in diabetes-associated atherosclerosis. Atherosclerosis 223: 144–151.
[25]
Gaster M, Kristensen SR, Beck-Nielsen H, Schroder HD (2001) A cellular model system of differentiated human myotubes. APMIS 109: 735–744.
[26]
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254.
[27]
Johansen HT, Knight CG, Barrett AJ (1999) Colorimetric and fluorimetric microplate assays for legumain and a staining reaction for detection of the enzyme after electrophoresis. Anal Biochem 273: 278–283.
[28]
Barrett AJ, Kirschke H (1981) Cathepsin B, Cathepsin H, and cathepsin L. Methods Enzymol. 80: 535–561.
[29]
Werle B, Ebert W, Klein W, Spiess E (1995) Assessment of cathepsin L activity by use of the inhibitor CA-074 compared to cathepsin B activity in human lung tumor tissue. Biol Chem Hoppe Seyler 376: 157–164.
[30]
Wensaas AJ, Rustan AC, Lovstedt K, Kull B, Wikstrom S, et al. (2007) Cell-based multiwell assays for the detection of substrate accumulation and oxidation. J Lipid Res 48: 961–967.
[31]
Takaguri A, Satoh K, Itagaki M, Tokumitsu Y, Ichihara K (2008) Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes. J Pharmacol Sci 107: 80–89.
[32]
Aas V, Bakke SS, Feng YZ, Kase ET, Jensen J, et al. (2013) Are cultured human myotubes far from home? Cell Tissue Res.
[33]
Colella R, Roisen FJ, Bird JW (1986) mRNA levels of cathepsins B and D during myogenesis. Biomed Biochim Acta 45: 1413–1419.
[34]
Qian F, Chan SJ, Gong QM, Bajkowski AS, Steiner DF, et al. (1991) The expression of cathepsin B and other lysosomal proteinases in normal tissues and in tumors. Biomed Biochim Acta 50: 531–540.
[35]
Koh KK, Quon MJ, Han SH, Lee Y, Ahn JY, et al. (2008) Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 31: 776–782.
[36]
Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, et al. (2010) Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 55: 1209–1216.
[37]
Park SY, Choi GH, Choi HI, Ryu J, Jung CY, et al. (2005) Depletion of mitochondrial DNA causes impaired glucose utilization and insulin resistance in L6 GLUT4myc myocytes. J Biol Chem 280: 9855–9864.
[38]
Minet AD, Gaster M (2010) ATP synthesis is impaired in isolated mitochondria from myotubes established from type 2 diabetic subjects. Biochem Biophys Res Commun 402: 70–74.
[39]
Stevens TH, Forgac M (1997) Structure, function and regulation of the vacuolar (H+)-ATPase. Annu Rev Cell Dev Biol 13: 779–808.
[40]
Deng D, Jiang N, Hao SJ, Sun H, Zhang GJ (2009) Loss of membrane cholesterol influences lysosomal permeability to potassium ions and protons. Biochim Biophys Acta 1788: 470–476.
[41]
Jadot M, Andrianaivo F, Dubois F, Wattiaux R (2001) Effects of methylcyclodextrin on lysosomes. Eur J Biochem 268: 1392–1399.
[42]
Subtil A, Gaidarov I, Kobylarz K, Lampson MA, Keen JH, et al. (1999) Acute cholesterol depletion inhibits clathrin-coated pit budding. Proc Natl Acad Sci U S A 96: 6775–6780.
[43]
Pike LJ, Miller JM (1998) Cholesterol depletion delocalizes phosphatidylinositol bisphosphate and inhibits hormone-stimulated phosphatidylinositol turnover. J Biol Chem 273: 22298–22304.
[44]
Peres C, Yart A, Perret B, Salles JP, Raynal P (2003) Modulation of phosphoinositide 3-kinase activation by cholesterol level suggests a novel positive role for lipid rafts in lysophosphatidic acid signalling. FEBS Lett 534: 164–168.
[45]
Minogue S, Chu KM, Westover EJ, Covey DF, Hsuan JJ, et al. (2010) Relationship between phosphatidylinositol 4-phosphate synthesis, membrane organization, and lateral diffusion of PI4KIIalpha at the trans-Golgi network. J Lipid Res 51: 2314–2324.
[46]
Waugh MG, Minogue S, Chotai D, Berditchevski F, Hsuan JJ (2006) Lipid and peptide control of phosphatidylinositol 4-kinase IIalpha activity on Golgi-endosomal Rafts. J Biol Chem 281: 3757–3763.
[47]
Flint OP, Masters BA, Gregg RE, Durham SK (1997) HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. Toxicol Appl Pharmacol 145: 99–110.
[48]
Stenmark H (2009) Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol 10: 513–525.
Skottheim IB, Gedde-Dahl A, Hejazifar S, Hoel K, Asberg A (2008) Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. Eur J Pharm Sci 33: 317–325.
[51]
Itagaki M, Takaguri A, Kano S, Kaneta S, Ichihara K, et al. (2009) Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats. J Pharmacol Sci 109: 94–101.
